Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 65
    records per page

    The case series of 34 patients with COVID-19 diagnosed with HIV infection MESHD from Central and Eastern European Countries - Euroguidelines in Central and Eastern Europe Network Group data

    Authors: Kerstin Kase; Agata Skrzat-Klapaczynska; Anne Vassilenko; Arjan Harxhi; Botond Lakatos; Gordana Dragovic Lukic; David Jilich; Antonija Verhaz; Nina Yancheva; Florentina Dumitrescu; Raimonda Matulionyte; Andrzej Horban; Justyna Dominika Kowalska; Michela Sali; Massimiliano Papi; Jayashree Kalpathy-Cramer; Fredrik Nyberg; Jose D Posada; Martina Recalde; Elena Roel; Karishma Shah; Nigam Shah; Lisa M Schilling; Vignesh Subbian; David Vizcaya; Lin Zhang; Ying Zhang; Hong Zhu; Li Liu; Peter Rijnbeek; George Hripcsak; Jennifer C.E Lane; Edward Burn; Christian Reich; Marc A Suchard; Talita Duarte-Salles; Krisitn Kosta; Patrick B Ryan; DANIEL PRIETO-ALHAMBRA; Christoph Lange; Georg Laue; Clemes Lier; Matthias Lindner; Georgios Marinos; Robert Markewitz; Jacob Nattermann; Rainer Noth; Peter Pickkers; Klaus F. Rabe; Alina Renz; Christoph Roecken; Jan Rupp; Annika Schaffarzyk; Alexander Scheffold; Jonas Schulte-Schrepping; Domagoj Schunck; Dirk Skowasch; Thomas Ulas; Klaus-Peter Wandinger; Michael Wittig; Johannes Zimmermann; Hauke Busch; Bimba F. Hoyer; Christoph Kaleta; Jan Heyckendorf; Matthijs Kox; Jan Rybniker; Stefan Schreiber; Joachim Schultze; Philip Rosenstiel; - HCA Lung Biological Network; - Deutsche COVID-19 Omics Initiative (DeCOI)

    doi:10.1101/2020.09.16.20191528 Date: 2020-09-18 Source: medRxiv

    Background: A novel coronavirus (SARS-CoV-2) causing coronavirus disease MESHD (COVID-19) was detected at the end of 2019 in China. There are many COVID-19 studies in progress however, little is known about the course of COVID-19 in people living with HIV MESHD (PLWH). The aim of our study was to describe epidemiology and clinical characteristics of PLWH diagnosed with COVID-19 reported form Central and Eastern European Countries. Methods: On-line survey was sent to Euroguidelines in Central and Eastern Europe (ECEE) Network Group. Analysis included all confirmed COVID-19 cases between March 11 and June 26 2020 among PLWH in 12 countries: Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Czech Republic, Estonia, Hungary, Lithuania, Poland , Romania, Russia MESHD, and Serbia. Results: In total 34 cases were reported. The mean age TRANS of those patients was 42.7 years (IQR=35.8-48.5) and most of the patients were male TRANS (70.6% vs 29.4%). The mean CD4+ T-cell count prior COVID-19 diagnosis was 558 cells/mm3 (IQR=312-719) and HIV MESHD RNA viral load (VL) was undetectable in 18 of 34 (53%) cases, the data about most recent HIV RNA VL was not available in three cases (8,8%). Comorbidities were observed in 19 (55.9%) patients, mostly cardiovascular disease MESHD (27,8%), and in 10 (29.4%) patients had coinfection, mostly chronic hepatitis HP chronic hepatitis MESHD C (87.5%). The clinical course of COVID-19 was asymptomatic TRANS in 4 (12%) cases, mild disease without hospitalization was reported in 11 (32%) cases. Stable patients with respiratory and/or systemic symptoms have been documented in 14 (41%) cases; 5 (15%) patients were clinically unstable with respiratory failure HP respiratory failure MESHD. Full recovery was reported in 31 (91%) cases, two patients died. In one case the data was not available. Conclusion: This study from 12 countries in Central and Eastern Europe region indicates no alarming signals of increased morbidity or mortality from COVID-19 among HIV-positive persons there is a need for further research.

    No association between circulating levels of testosterone and sex hormone-binding globulin and risk of COVID-19 mortality in UK biobank

    Authors: Xikang Fan; Jing Yang; Jiayu Wang; Cheng Yin; Meng Zhu; Hongxia Ma; Guangfu Jin; Zhibin Hu; Hongbing Shen; Dong Hang; Roland M. Schmid; Tobias Lahmer; Wolfgang Huber; Xiushan Yin; Arsen Arakelyan; Denise Haslwanter; Rohit Jangra; Alev Celikgil; Duncan Kimmel; James H Lee; Margarette Mariano; Antonio Nakouzi; Jose Quiroz; Johanna Rivera; Wendy A Szymczak; Karen Tong; Jason Barnhill; Mattias NE Forsell; Clas Ahlm; Daniel T. Stein; Liise-anne Pirofski; Doctor Y Goldstein; Scott J. Garforth; Steven C. Almo; Johanna P. Daily; Michael B. Prystowsky; James D. Faix; Amy S. Fox; Louis M. Weiss; Jonathan R. Lai; Kartik Chandran

    doi:10.1101/2020.09.11.20191783 Date: 2020-09-11 Source: medRxiv

    Background: Sex-disaggregated data suggest that men with coronavirus disease MESHD 2019 (COVID-19) are more likely to die than women. Whether circulating testosterone or sex hormone-binding globulin (SHBG) contributes to such sex differences remains unknown. Objective: To evaluate the associations of circulating total testosterone (TT), free testosterone (FT), and SHBG with COVID-19 mortality. Design: Prospective analysis. Setting: UK Biobank. Participants: We included 1306 COVID-19 patients (678 men and 628 women) who had serum SERO TT and SHBG measurements and were free of cardiovascular disease MESHD or cancer MESHD at baseline (2006-2010). Main outcome measures: The death cases of COVID-19 were identified from National Health Service death records updated at 31 July 2020. Unconditional logistic regression was performed to estimate the odds ratio (OR) and 95% confidence intervals (CI) for mortality. Results: We documented 315 deaths of COVID-19 (194 men and 121 women). After adjusting for potential confounders, we did not find any statistically significant associations for TT (OR per 1-SD increase = 1.03, 95% CI: 0.85-1.25), FT (OR per 1-SD increase = 0.95, 95% CI: 0.77-1.17), or SHBG (OR per 1-SD increase = 1.09, 95% CI: 0.87-1.37) with COVID-19 mortality in men. Similar null results were observed in women (TT: OR per 1-SD increase = 1.10, 95% CI: 0.85-1.42; FT: OR per 1-SD increase = 1.10, 95% CI: 0.82-1.46; SHBG: OR per 1-SD increase = 1.16, 95% CI: 0.89-1.53). Conclusions: Our findings do not support a significant role of circulating testosterone or SHBG in COVID-19 prognosis.

    Burden and prevalence SERO of risk factors for severe COVID-19 disease in the ageing European population – A SHARE-based analysis

    Authors: Linda Juel Ahrenfeldt; Camilla Riis Nielsen; Sören Möller; Kaare Christensen; Rune Lindahl-Jacobsen

    doi:10.21203/ Date: 2020-09-07 Source: ResearchSquare

    Aim: International health authorities suggest that individuals aged TRANS 65 years and above and people with underlying comorbidities such as hypertension HP hypertension MESHD, chronic lung disease HP lung disease MESHD, cardiovascular disease MESHD, cancer MESHD, diabetes MESHD, and obesity HP obesity MESHD are at increased risk of severe Coronavirus Disease MESHD 2019 (COVID-19); however, the prevalence SERO of risk factors is unknown in many countries. Therefore, we aim to describe the distribution of these risk factors across Europe. Subject and Methods: Prevalence SERO of risk factors for severe COVID-19 was identified based on interview for 73,274 Europeans aged TRANS 50+ participating in the Survey of Health, Ageing and Retirement in Europe (SHARE) in 2017. Burden of disease was estimated using population data from Eurostat. Results: A total of 75.3% of the study population (corresponding to app. 60 million European men and 71 million women) had at least one risk factor for severe COVID-19, 45.9% (app. 36 million men and 43 million women) had at least two factors and 21.2% (app. 17 million men and 20 million women) had at least three risk factors. The prevalences SERO of underlying medical conditions ranged from 4.5% for cancer MESHD to 41.4% for hypertension HP hypertension MESHD, and the region-specific prevalence SERO of having at least three risk factors ranged from 18.9% in Northern Europe to 24.6% in Eastern Europe. Conclusions: Information about the prevalences SERO of risk factors might help authorities to identify the most vulnerable subpopulations with multiple risk factors of severe COVID-19 disease MESHD and thus to decide appropriate strategies to mitigate the pandemic.  

    Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy HP cardiomyopathy MESHD and venous thromboembolism MESHD thromboembolism HP

    Authors: Grant E Castaneda; Abby C Lee; Wei Tse Li; Chengyu Chen; Jaideep Chakladar; Eric Chang; Weg Ongkeko; Xiaojian Liu; Wei Gao; Renli Zhang; Qiru Su; Andrew Azman; Justin Lessler; Xuan Zou; Wenfeng Gong; Brenda Clemente; Jerel Vega; Scott Roberts; Jose A. Gonzalez; Marciano Sablad; Rodrigo Yelin; Wendy Taylor; Kiyoshi Tachikawa; Suezanne Parker; Priya Karmali; Jared Davis; Sean M Sullivan; Steve G. Hughes; Pad Chivukula; Eng Eong Ooi

    doi:10.1101/2020.08.28.20184234 Date: 2020-09-02 Source: medRxiv

    As of 28 August 2020, there have been 5.88 million Coronavirus Disease MESHD 2019 (COVID-19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence SERO of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease MESHD and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation HP that accompanies cardiovascular disease MESHD predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation HP dysregulation MESHD in patients with cardiomyopathy HP cardiomyopathy MESHD, venous thromboembolism MESHD thromboembolism HP and COVID-19 patients by looking at immune-associated gene dysregulation, immune HP infiltration and dysregulated immunological pathways and gene signatures.

    Cardiomegaly HP Cardiomegaly MESHD found in the 2019 Novel Coronavirus Disease MESHD (COVID-19): Analysis of 115 Patients

    Authors: Zeinab Shankayi; Farideh Bahrami; Tahereh Mohammadzadeh; Amineh Ghafari Anvar; Hosein Amini; M. Mehdi Asadi; M.Hossein Mirasheh; Mojtaba Sharti

    doi:10.21203/ Date: 2020-09-01 Source: ResearchSquare

    Objectives There is much evidence showing that most of the mortality and morbidity cases are observed in COVID-19 patients with cardiovascular diseases MESHD. Thus, the study on COVID 19 patients with cardiovascular diseases MESHD is required for their optimum management. The present study presents a preliminary report on the cardiomegaly HP cardiomegaly MESHD of laboratory and CT findings of COVID-19 pneumonia HP pneumonia MESHD in Iran. A total of 115 Patients with COVID-19 pneumonia HP pneumonia MESHD hospitalized in (confirmed by CT scan and RT-PCR) Baghiyatallah hospital participated in the present study.Results Thirty-three of these patients (26.8%) had cardiomegaly HP cardiomegaly MESHD detected by chest CT scan. Creatinine, Urea and CRP levels of patients significantly increased based on cardiovascular disease MESHD detection. In contrast, Sodium levels reduced to below the normal in patients with cardiomegaly HP cardiomegaly MESHD. Despite respiratory illness as the first symptom of COVID-19, the role of other diseases such as cardiovascular disease MESHD requires further investigation.

    Clinical Characteristics and Outcomes of COVID-19 Positive Acute Coronary Syndrome MESHD Patients; a multisource Electronic Healthcare Records Study from England

    Authors: Muhammad Rashid; Jianhua Wu; Adam Timmis; Nick Curzen; Azfar Zaman; Sarah Clarke; James Nolan; Ahmad Shoiab; Mohamed O Mohamed; Mark De Belder; John Deanfield; Chris Gale; Mamas Mamas; Ian Reckless; Tim Brooks; Andre Charlett; Matthew Hickman; Isabel Oliver; David Wyllie

    doi:10.1101/2020.08.20.20175091 Date: 2020-08-22 Source: medRxiv

    Background: Patients with underlying cardiovascular disease MESHD and Coronavirus disease MESHD 2019 (COVID-19) infection MESHD are at increased risk of morbidity and mortality. However, there is limited information on management and outcomes of patients presenting with acute coronary syndrome MESHD ( ACS MESHD) and concomitant COVID19 infection MESHD. Objectives: This multisource national analysis of live data from England was designed to characterise the presenting profile and outcomes of patients hospitalized with ACS MESHD and COVID-19 infection MESHD. Methods: Multisource data from all acute NHS hospital in England was linked to study the characteristics and outcomes of patients hospitalized with COVID-19 ACS MESHD compared to non COVID-19 ACS MESHD patients. Hierarchical multilevel models were constructed to study the association between COVID19 ACS MESHD and in-hospital and 30-day mortality. Results: Between 1st March 2020 and 31st May 2020, 517 (4.0%) were admitted with COVID- 19 ACS MESHD from a total of 12,958 ACS MESHD patients. COVID-19 ACS MESHD patients were generally older, BAME ethnicity, more comorbid and had unfavourable presenting characteristics compared to non-COVID-19 ACS MESHD patients. They were less likely to receive invasive coronary strategy in the form of coronary angiography (67.7% vs 81.0%), PCI (30.2% vs 53.9%), dual antiplatelet medication 76.3% vs 88.0%), and other important secondary medication. Patients with COVID-19 ACS MESHD had higher in-hospital (aOR 3.27 95%CI 2.41-4.42) and 30-day mortality (aOR 6.53 95%CI 5.1-8.36) compared to non COVID-19 ACS MESHD group. Conclusion: COVID-19 infection MESHD is prevalent but less frequent in the patients hospitalized with ACS MESHD in England. Presence of COVID-19 infection MESHD in patients with ACS MESHD is associated with significant mortality hazard.

    Abnormal Upregulation of Cardiovascular Disease MESHD Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients

    Authors: Yang LI; Yongzhong JIANG; Yi ZHANG; Naizhe LI; Qiangling YIN; Linlin LIU; Xin LV; Yan LIU; Aqian LI; Bin FANG; Jiajia LI; Hengping YE; Gang YANG; Xiaoxian CUI; Yang LIU; Yuanyuan QU; Chuan LI; Jiandong LI; Dexin LI; Shiwen WANG; Zhongtao GAI; Faxian ZHAN; Mifang LIANG; Scott Hensley

    doi:10.1101/2020.08.16.20175505 Date: 2020-08-18 Source: medRxiv

    BACKGROUND. Coronavirus disease MESHD 2019 (COVID-19) triggers distinct patterns of pneumonia HP pneumonia MESHD progression with multiorgan disease, calling for cell- and/or tissue-type specific host injury markers. METHODS. An integrated hypothesis-free single biomarker analysis framework was performed on nasal swabs (n=484) from patients with COVID-19 in GSE152075. The origin of candidate biomarker was assessed in single-cell RNA data (GSE145926). The candidate biomarker was validated in a cross-sectional cohort (n=564) at both nucletide and protein levels. RESULTS. Phospholipase A2 group VII (PLA2G7) was identified as a candidate biomarker in COVID-19. PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, PLA2G7 was found in patients with COVID-19 and pneumonia HP pneumonia MESHD, especially in severe pneumonia HP pneumonia MESHD, rather than patients suffered mild H1N1 influenza infection MESHD. The positive rates of PLA2G7 ranging from 29.37% to 100.00% were positively correlated with not only viral loads in patients with COVID-19 but also severity of pneumonia HP pneumonia MESHD in non COVID-19 patients. Although Ct values of PLA2G7 in severe pneumonia HP pneumonia MESHD was siginificantly lower than that in moderate pneumonia HP pneumonia MESHD (P=7.2e-11), no differences were observed in moderate pneumonia HP pneumonia MESHD with COVID-19 between severe pneumonia HP pneumonia MESHD without COVID-19 (P=0.81). Serum SERO protein levels of PLA2G7, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2), were further found to be elevated and beyond the upper limit of normal in patients with COVID-19, especially among the re-positive patients. CONCLUSIONS. We firstly identified and validated PLA2G7, a biomarker for cardiovascular diseases MESHD ( CVDs MESHD), was abnormally enhanced in COVID-19 patients at both nucletide and protein aspects. These findings provided indications into the prevalence SERO of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a hallmark of COVID-19 for monitoring disease progress and therapeutic response.

    Causal associations between COVID-19 and Atrial Fibrillation HP Atrial Fibrillation MESHD: A bidirectional Mendelian randomization study

    Authors: Xiaoyu Zhang; Biyan Wang; Di Liu; Jinxia Zhang; Qiuyue Tian; Xiaoni Meng; Jie Zhang; Haifeng Hou; Manshu Song; Wei Wang; Youxin Wang; Steven Y Chang; Tisha Wang; Nida Qadir; Rachel Vreeman; Joseph Masci; Nick A Maskell; Shaney Barratt

    doi:10.1101/2020.08.13.20174417 Date: 2020-08-14 Source: medRxiv

    Abstract Background Observational studies showed that coronavirus disease MESHD 2019 (COVID-19) attacks universally and its most menacing progression uniquely endangers the elderly TRANS with cardiovascular disease MESHD ( CVD MESHD). Whether COVID-19 is causally related to increasing susceptibility and severity of atrial fibrillation HP atrial fibrillation MESHD ( AF MESHD), the main form of CVD MESHD, remains still unknown. Methods The study aims to investigate the bidirectional causal relations of COVID-19 with AF MESHD using two-sample Mendelian randomization (MR) analysis. Results MR evidence suggested genetically predicted severe COVID-19 was significantly associated with higher risk of AF MESHD (odds ratio [OR], 1.041; 95% confidence interval (CI), 1.007-1.076; P = 0.017), while genetically predicted AF MESHD was not causally associated with severe COVID-19 (OR, 0.831; 95% CI, 1.619-1.115; P=0.217). There was limited evidence to support association of genetically proxied COVID-19 with risk of AF MESHD (OR, 1.051; 95% CI, 0.991-1.114; P=0.097), and vice versa (OR, 0.163; 95% CI, 0.004-6.790; P=0.341). MR-Egger indicated no evidence of pleiotropic bias MESHD. Conclusion Overall, severe COVID-19 may causally affect AF MESHD through independent biological pathway. Survivors from severe COVID-19 might be of high risk of AF MESHD in the future. Key words Coronavirus disease MESHD 2019; Atrial Fibrillation HP Atrial Fibrillation MESHD; Bidirectional mendelian randomization

    Acute Lung injury MESHD evolution in Covid-19

    Authors: Claudio Doglioni; Claudia Ravaglia; Giulio Rossi; Alessandra Dubini; Federica Pedica; Sara Piciucchi; Antonio Vizzuso; Lorenza Pecciarini; Franco Stella; Stefano Maitan; Vanni Agnoletti; Emiliano Gamberini; Emanuele Russo; Silvia Puglisi; Antonella Arcadu; Luca Donati; Simona Di Cesare; Carmela Grosso; Giovanni Poletti; Vittorio Sambri; Elisabetta Fabbri; Giovanni Pizzolo; Stefano Ugel; Vincenzo Bronte; Athol U Wells; Marco Chilosi; Venerino Poletti; Tobias Boettler; Bertram Bengsch; Robert Thimme; Maike Hofmann; Christoph Neumann-Haefelin

    doi:10.1101/2020.08.09.20170910 Date: 2020-08-13 Source: medRxiv

    BACKGROUND Pathogenesis of Coronavirus disease MESHD 2019 (Covid-19) is poorly understood. Most histologic studies come from post-mortem analysis, with existing data indicating that histologic features of acute respiratory distress syndrome MESHD respiratory distress HP syndrome are typically present in fatal cases. However, this observation may be misleading, due to confounding factors in pre-terminal disease, including injury resulting from prolonged mechanical ventilation. Ante-mortem lung biopsy may provide major pathogenetic insights, potentially providing a basis for novel treatment approaches. AIM This comparative, multicenter, prospective, observational study was planned to identify ante-mortem histological profile and immunohistochemical features of lung tissue in patients with Covid-19 in early and late phases of the disease, including markers of inflammatory cells and major pathways involved in the cytokine storm triggering. METHODS Enrolled patients underwent lung biopsy, according to the study protocol approved by local Ethical Committee, either within 15 days of the first symptoms appearing (early phase) or after > 15 days (more advanced disease). Key exclusion criteria were excessive or uncorrectable bleeding MESHD risk and cardiovascular disease MESHD with heart failure MESHD. Lung samples were obtained by conventional trans-bronchialbiopsy, trans-bronchial lung cryobiopsy or surgical lung biopsy. RESULTS 23 patients were enrolled: 12 patients underwent lung biopsy within 15 days and 11 patients more than 15 days after the onset of symptoms TRANS. Early biopsies were characterized by spots of patchy acute lung injury MESHD ( ALI MESHD) with alveolar type II MESHD cells hyperplasia MESHD and significant vascular abnormalities MESHD (disordered angiogenesis with alveolar capillary hyperplasia, luminal enlargement MESHD and thickened walls of pulmonary venules, perivascularCD4-T-cell infiltration), with no hyaline membranes. In the later stages, the alveolar architecture MESHD appeared disrupted, with areas of organizing ALI MESHD, venular congestion and capillary thromboembolic microangiopathy MESHD. Striking phenotypic features were demonstrated in hyper plastic pneumocytes MESHD and endothelial cells, including the expression of phospho-STAT3 and molecules involved in immunoinhibitory signals (PD-L1 and IDO1). Alveolar MESHD macrophages exhibited macrophage-related markers (CD68, CD11c, CD14) together with unusual markers, such as DC-Lamp/CD208, CD206, CD123/IL3AR. CONCLUSION A morphologically distinct Covid pattern was identified in the earlier stages of the disease, with prominent epithelial and endothelial cell abnormalities, that may be potentially reversible, differing strikingly from findings in classical diffuse alveolar damage MESHD. These observations may have major therapeutic implications, justifying studies of early interventions aimed at mitigating inflammatory organ injury.

    Observations on echocardiographic findings in patients with COVID-19

    Authors: Ahsan A Khan; Sunil James; Mengshi Yuan; Latoya Woolery; Nina Huppertz; Mushidur Rahman; Chetan Varma; Stavros Apostolakis; Vinoda Sharma

    doi:10.21203/ Date: 2020-08-12 Source: ResearchSquare

    Background The novel coronavirus (SARS-CoV-2) has created global havoc by causing Coronavirus Disease MESHD 2019 (COVID-19). Cardiovascular involvement MESHD in COVID-19 varies from troponin rise or arrhythmia HP arrhythmia MESHD/ myocarditis HP myocarditis MESHD to fulminant cardiogenic shock HP cardiogenic shock MESHD. There is limited data on echocardiographic findings in such patients. We aimed to assess abnormal echocardiographic findings and contributory factors in patients with COVID-19.Methods We performed retrospective analysis of COVID-19 positive patients who underwent a transthoracic echocardiogram (TTE) at Sandwell and West Birmingham (SWBH) NHS Trust between March 2020 and May 2020. Patients were compared based on TTE changes and divided into two groups (abnormal TTE and normal TTE).Results 66 out of 463 patients with COVID-19 had a TTE. 46 patients (69.7%) had abnormal findings on their TTE. Tricuspid regurgitation HP Tricuspid regurgitation MESHD was the most common abnormality observed (26 (56.5%) patients), followed by aortic regurgitation HP aortic regurgitation MESHD (13 (28.3%) patients) and mitral regurgitation HP mitral regurgitation MESHD (12 (26.1%) patients). Haemoglobin and LDH were predictors of abnormal TTE (Hb OR: 0.97, p = 0.049, LDH, OR: 1.00, p = 0.03). Significantly more patients in the abnormal TTE group died during their inpatient stay compared to normal TTE (p = 0.01). Having an abnormal TTE was an independent predictor of death on regression analysis (OR: 0.229, p = 0.034).Conclusions This is the first detailed observational study looking at echocardiographic changes in admitted COVID-19 patients irrespective of disease severity. The most common abnormality was valve regurgitation MESHD. Patients with abnormal TTE were more likely to die in hospital.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.